PharmaTelevision - Prosensa: Luc Dochez. Using their RNA modulating platform to help patients with Duchenne's, Myotonic Dystrophy and Huntington’s.

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Prosensa: Luc Dochez. Using their RNA modulating platform to help patients with Duchenne's, Myotonic Dystrophy and Huntington’s.

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Luc Dochez, Chief Business Officer and SVP Business Development of Prosensa.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Focus on duchenne muscular dystrophy

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO-Europe in Duesseldorf in 2011. On this show I have Luc Dochez, who is a Senior Vice President of Business Development and Chief Business Officer at a company called Prosensa based in Holland, welcome to the show.

Luc Dochez:

Thank you.

Fintan Walton:

Luc, you've been on the show before and you've introduced Prosensa to our audience may be you can just give us a reminder of Prosensa and what you are focused on?

Luc Dochez:

Well happy to do that. So Prosensa is a company focused on rare diseases specifically working on RNA modulation platform and we try to help patients with genetic disorders, rare genetic disorders for whom there is no current treatment available and our main focus is on Duchenne Muscular Dystrophy where we have a lead program now in partnership with GlaxoSmithKline in Phase III development , but we have many more compounds following that lead compound as I can explain later in the show how that exactly works.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Luc Dochez

Chief Business Officer

At the time of recording this PTV interview Luc Dochez works as Chief Business Officer and SVP Business Development of Prosensa. Luc Dochez, Chief Business Officer and Senior Vice-President Business Development joined Prosensa in November 2008 and is responsible for all business and corporate development activities at the company. He has over 10 years experience in the biotech industry and was directly involved in multiple financing rounds and partnering deals with various biotech companies. Before joining Prosensa, he was a consultant within Arthur D. Little's biotechnology practice, Director of Business Development at Methexis Genomics NV, VP Business Development at TiGenix NV and President of TiGenix Inc. Luc holds a PharmD degree from the University of Leuven (Belgium), a postgraduate degree in Business Economics from the same university and an MBA from Vlerick Management School.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Prosensa

Prosensa is a biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy (DM1), Huntington's Disease (HD) and Spinal Muscular Atrophy (SMA). The company has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy . Its lead product, PRO051/GSK2402968, aims at restoring dystrophin expression and improving muscle condition and function in a relatively large subpopulation of duchenne patients and has successfully completed a Phase I/II study. Preparations are ongoing to start enrolling patients in a Phase III study in 2010. PRO044, the company's second product candidate, addresses another subpopulation of duchenne patients and has entered clinical trials in the last quarter of 2009. Prosensa was founded in 2002 and is located in Leiden, The Netherlands. The company works closely together with Leiden University Medical Center (LUMC) and is supported by a consortium of leading biotech investors, including Abingworth, Life Sciences Partners, Gimv, AGF and MedSciences Capital. In October 2009, Prosensa entered into a strategic alliance with GlaxoSmithKline (GSK) to accelerate and broaden the development of its DMD product candidates.